OFFICIAL NOTICE CONTENT
Opportunity description
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Progenics Pharmaceuticals Inc. The National Institute of Health, Clinical Center (NIH-CC)�s has the Nuclear Pharmacy (CC NP) department (collectively �Program�) that purchases and compounds radiopharmaceuticals (radioactive drugs) on a daily basis for life-saving clinical nuclear medicine procedures. This is essential for the NIH Clinical Center to achieve optimal patient care. These radiopharmaceuticals are United States Food and Drug Administration (FDA) approved drugs for use in patients. They are also radioactive materials that are regulated by the United States Nuclear Regulatory Commission (US NRC) through the NIH radioactive material license (RAM) administered by the NIH Radiation Safety Office (RSO). Only RSO certified Nuclear Medicine personnel can order these radiopharmaceuticals directly for patient use. Each radiopharmaceutical is time sensitive because of the rapid radiation decay. Because of their short useful half-lives, they cannot be ordered in advance for storage. They must be properly compounded, dispensed, calibrated and delivered for a specific patient at a specific time on a specific date on a daily basis. The purpose is to procure compounded piflufolasta F-18 in patient ready unit doses (UDs) from an authorized nuclear pharmacy for the use by the NIH Nuclear Medicine, Department of Radiology and Imaging Sciences to diagnose and treat diseases as required by necessary patient care protocols at the NIH Clinical Center. This new radioactive drug is vital to the NIH Clinical Center mission. The product is owned and developed by Lantheus Medical/Progenics Pharmaceuticals (now merged as one company). Progenics Pharmaceuticals Inc uses Lantheus� Federal Supply Schedule contract on contract 36F79719D0170. Justification and other information: This requirement will be sole sourced to Progenics Pharmaceuticals Inc. under FAR 8.405-6 (b): Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized. This notice is being made on SAM.gov instead of GSA Ebuy because the GSA Ebuy category �65 I B PHARMACEUTICALS AND DRUGS� states that �This SIN is not available through GSA Advantage.� Lantheus Medical Imaging (a company of Lanntheus Holding, Inc.) is the developer and intellectual property owner of Piflufolastat F-18 injection drugs (Pylarify) in the United States. More specifically, Progenics Pharmceuticals had been developing this drug and Lantheus merged Progenics Pharmaceuticals. Progenics Pharmaceuticals Inc is the only local authorized commercial nuclear pharmacy authorized by Lanthesus Medical Imaging to compound, prepare, delivery and invoice for these drugs. They use the Federal Supply Schedule contract on contract 36F79719D0170, and they are the designated authorized vendor for our area. Only this drug can be used for Program�s patient care and research and Program has been using these drugs for years in ongoing projects and patient care. Only qualified vendors that meet the FDA and US NRC regulations can provide these radiopharmaceuticals for compounding and dispensing at NIH Nuclear Pharmacy to NIH Clinical Center patients. Thus, only Progenics Pharmaceuticals Inc. is the sole authorized provider of these drugs. Indefinite Delivery/Indefinite Quantity (IDIQ) Requirement: 150x to 230x Qty of PYLARIFY piflufolastat F-18 injections 4x Qty for PYLARIFY unused doses fees Base Year Option Year 1 Option Year 2 Option Year 3 Option Year 4 Place of Performance or Delivery: The contract period of performance is 10/01/2026 � 09/30/2027 for the base year. Option Years: 10/01/2027 � 09/30/2028 10/01/2028 � 09/30/2029 10/01/2029 � 09/30/2030 10/01/2030 � 09/30/2031 This requirement will be awarded on GSA Contract #36F79719D0170. Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 and/or FAR 8.405-6 - only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-000004) by 10:00 AM eastern standard time on 09/29/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
FEDERAL BUYER
Buyer and contracting office
Public points of contact
DOCUMENTS & LINKS
Opportunity documents
That does not mean there are no documents. Open the current SAM.gov notice to see the authoritative attachment and amendment list.
GovBidFit does not invent or cache guessed attachment links. The official SAM.gov notice remains the controlling document source.
NOTICE TIMELINE
GovBidFit change history
This timeline records when GovBidFit first stored the notice and material field changes detected during scheduled SAM.gov refreshes. It is an audit aid, not a substitute for the official amendment history.
GovBidFit first stored this opportunity from the SAM.gov public bulk feed. This does not replace the official posting date shown above.
GOVBIDFIT SCREENING LENS
What deserves attention before you spend bid time
These screening signals are generated from the public notice fields stored for this specific opportunity. They are not eligibility findings or predictions; they are prompts for a faster, more disciplined review of the official solicitation.
This is a pre-solicitation signal. Use it to prepare, verify likely eligibility and watch for the formal solicitation or amendments before committing proposal effort.
The stored deadline is within three days. Check earlier question, site-visit and attachment requirements immediately; the final response date may not be the first deadline that matters.
The current feed does not show a program-specific set-aside restriction. That does not remove other eligibility, responsibility, registration or solicitation-specific requirements.
NAICS 325412 · PSC 6505 is the recorded classification. Use it as a screening clue, then compare the actual scope and deliverables rather than treating the code alone as proof of fit.
GovBidFit stores the source notice text, but its length does not prove the requirements are complete. Review official attachments, clauses, amendments and Q&A before relying on the description.
The source data includes 1 public contracting contact. Use the solicitation's stated communication rules and deadlines before contacting the buyer.
Questions to resolve next
What this opportunity record tells you
SAM.gov identifies this as a presolicitation from HEALTH AND HUMAN SERVICES, DEPARTMENT OF. The record was posted on September 22, 2026 and currently lists September 29, 2026 as the response deadline. GovBidFit keeps source facts separate from its matching guidance so you can see what comes from the federal notice.
The listed product or service classification is NAICS 325412 · PSC 6505. The set-aside field is Unrestricted. These fields help narrow your search, but they do not replace the full solicitation, amendments, attachments, clauses or eligibility language on the official source.
Before deciding to bid
GovBidFit is independent and is not a U.S. government website. GovBidFit stores a structured mirror of SAM.gov public opportunity data in its own database and keeps the compact snapshot as a fallback. The official SAM.gov notice remains the controlling source. The official SAM.gov notice controls if anything here differs from the source or a later amendment.
Open the official SAM.gov notice →